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abstract
Chronic tendon lesions are degenerative conditions and may represent a failure to repair or remodel the
extracellular matrix after repeated micro-injury. Since TGF-b is strongly associated with tissue repair, we
investigated the expression of TGF-b isoforms (b1, b2 and b3) and their 2 signalling receptors (TGF-bRI
and TGF-bRII) in normal and pathological Achilles tendons. In all tissues, all 3 TGF-b isoforms and the 2
receptors were present at sites of blood vessels. Cells in the matrix showed no staining for TGF-b1 or b3,
while TGF-b2 was associated with cells throughout the normal cadaver tendon. Tissue from tendons with
pathological lesions showed an increase in cell numbers and percentage TGF-b2 expression. TGF-bRII
showed a wide distribution in cells throughout the tissue sections. As with TGF-b2, there was an increase in
the number of cells expressing TGF-bRII in pathological tissue. TGF-bRI was restricted to blood vessels
and was absent from the fibrillar matrix. We conclude that despite the presence and upregulation of TGF-
b2, TGF-b signalling is not propagated due to the lack of TGF-bRI. This might explain why chronic tendon
lesions fail to resolve and suggests that the addition of exogenous TGF-b will have little effect on chronic
tendinopathy.
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introduction
Tendon lesions (tendinopathies) are often chronic,
tending to occur in middle age, frequently in the
absence of trauma or remembered injury. Degener-
ation is commonly associated with most tendino-
pathies, since there is little evidence of inflammation
(Astro$ m & Rausing, 1995; Jarvinen et al. 1997;
Kannus, 1997). They are often associated with
‘overuse’, and are possibly the consequence of
repeated microtrauma and a failure to repair (Kannus,
1997). Repair of matrix injury requires the co-
ordinated control of successive phases of cell activity,
including cell recruitment, cell proliferation, matrix
synthesis and matrix remodelling. Consequently a
failure of any one of these activities may give rise to a
tendinopathy.
Transforming growth factor beta (TGF-b) is likely
to be an important factor in tendon pathology since it
plays a major role in tissue repair (Clark & Coker,
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1998). One of its most important roles is the
promotion of new matrix synthesis (Ignotz &
Massague, 1986; Roberts et al. 1986; Clark et al.
1997; Wang et al. 1999). There are 3 mammalian
isoforms of TGF-b (b1, b2 and b3) which are
differently expressed in a variety of connective tissues
including cartilage (Fukumura et al. 1998; Matsunaga
et al. 1999), bone (Horner et al. 1998), and muscle
(McLennan & Koishi, 1997). Differential activities of
the 3 isoforms in tissue healing have also been shown
(Shah et al. 1995; O’Kane & Ferguson, 1997;
Cordeiro et al. 1999), although their precise role is not
fully understood. First secreted in a 100 kDa latent
form, TGF-b is activated by proteolytic cleavage,
releasing a 25 kDa active dimer (Clark & Coker,
1998). Activity is mediated by 2 signalling receptors,
TGF-b receptor I (TGF-bRI) and TGF-bRII, which
dimerise and transduce their signal via their serine}
threonine kinase activity (Wrana et al. 1994).
There have been no studies of the expression and
Fig. 1. Haematoxylin and eosin staining (a, b, c) showing morphology of cells and tissue structure. Alcian blue staining (d, e, f ) showing
the presence (blue) or absence (pink) of glycosaminoglycans. Masson’s trichrome staining (g, h, i ) showing organised collagen matrix (red)
and disorganised collagen matrix (blue}green). Normal matrix organisation, normal cellularity and absence of glycosaminoglycan (GAG)
infiltration in a 76-y-old male cadaver (a, d, g). The macroscopically normal site of a 38-y-old male patient with Achilles tendinopathy also
showed normal organisation, normal cellularity and no GAG infiltration (b, e, h). The specimen from the site of the lesion in the same patient
with tendinopathy showed increased cellularity, cell rounding, infiltration of GAG and absence of matrix organisation (c, f, i ). ‹400.
role of TGF-b in human tendon pathology. Studies of
acute tendon lesions in animals, while informative,
have little relevance to the chronic degenerative lesions
found in man (Chang et al. 1997). There are alterations
in TGF-b expression in a number of connective tissue
pathologies such as Dupuytren’s contracture and
keloid scar (Park et al. 1995; Badalamente et al. 1996;
Ichiki et al. 1997), implicating TGF-b in the path-
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Fig. 2. Immunolocalisation of TGF-b isoforms, showing a lack of tenocyte staining for TGF-b1 (a, d, g) and TGF-b3 (c, f, i ). TGF- b2 was
localised to tenocytes throughout the tissues seen as dark brown staining of the cells (b, e, h). Blood vessels stained positively for TGF-b1
( j ), TGF-b2 (k) and TGF-b3 (l). a, b and c are from a 76-y-old male cadaver, d, e and f are from the macroscopically normal site of a 39-
y-old male, g, h and i are from the core lesion site of a 36-y-old male. Haematoxylin counterstain, ‹400.
ology. It has also been suggested that alterations in
responsiveness to TGF-b are the driving force behind
such pathologies (Bettinger et al. 1996; Zhou et al.
1997). TGF-b has been shown to have profound
effects on tissue repair (O’Kane & Ferguson, 1997)
and to accelerate and enhance wound healing as an
exogenously applied agent (Ksander et al. 1990; Beck
et al. 1991; Quaglino et al. 1991; Meyer, 1993;
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Robinson, 1993). However, before the use of TGF-b
therapy in tendon treatment, it is necessary to
determine which, if any, TGF-b isoforms and their
signalling receptors are present in chronic tendinosis.
This will subsequently allow further research into the
possible therapeutic value of TGF-b in tendinopathy.
Here we present the results of an immunochemical
study of all 3 TGF-b isoforms and their signalling
receptors in specimens taken from patients with
chronic tendinosis. Comparisons were then made with
samples of macroscopically and histologically normal
tendon tissue from the same tendon and with
unaffected Achilles tendons from cadavers.
materials and methods
Tissue
Achilles tendon tissue was obtained from patients
undergoing surgery for chronic Achilles tendinopathy
(nfl 7, aged 29–49 y, mean 38–4‡7–8 y). Macro-
scopically abnormal tissue was removed from the core
of the lesion, which was localised with the aid of
magnetic resonance imaging. All lesions were located
in the tendon midsubstance approximately 4–8 cm
from the tendon insertion. As part of the operative
procedure, macroscopically normal tissue was also
removed from each tendon from a site distant to the
core lesion. Normal Achilles tendon tissue was
obtained from cadavers, with no known history of
tendinopathy, no more than 48 h after death (nfl 4,
aged 56–93 y, mean 75–5‡15–2 y).
Tissue preparation
Tissue was immediately cut into small cubes and
either snap frozen in hexane before storage at fi70 °C,
or lightly fixed in 4% paraformaldehyde in phosphate
buffered saline on ice for 2–4 h followed by saturation
in cold 30% sucrose at 4 °C. Tissue was embedded in
Optimal Cutting Temperature compound (OCT, Agar
Scientific, Essex, UK) and cryosections cut at
8–10 lm. Sections were mounted on 3-aminopropyl-
triethoxysilane (TESPA, Sigma) coated slides and
allowed to air dry. Unfixed tissue sections were
subsequently fixed briefly in acetone for 30 s before
staining.
Histology and histochemistry
Sections were stained with haematoxylin and eosin to
display general morphology and cellularity and with
Alcian blue}periodic acid Schiff to demonstrate
matrix proteoglycans and glycosaminoglycans
(GAG). Masson’s trichrome stain as described by
Flint et al. (1975) was used to determine whether the
collagenous matrix was well organised or whether it
had lost the organised fibrillar structure associated
with normal tendon.
Immunohistochemistry
Immunochemical staining was performed for all 3
human TGF-b isoforms and for the 2 TGF-b
receptors. Antibodies to the 3 mammalian TGF-b
isoforms and the 2 signalling receptors were obtained
from Santa Cruz Biotechnology (California, USA).
All antibodies were affinity purified rabbit polyclonals
to the human epitopes. The 3 TGF-b antibodies were
isoform specific as confirmed by western blot analysis
and immunohistochemical staining (Frank et al. 1996),
while the receptor antibodies were confirmed to be
specific by immunoprecipitation (Brand & Schnieder,
1995). The anti-TGF-b antibodies do not differentiate
between active and latent TGF-b. Antibodies were
titrated against sections over a range of dilutions,
4 lg}ml, 2 lg}ml, 1 lg}ml and 0–4 lg}ml. Blood
vessels, which had previously been shown to express
all 3 TGF-b isoforms and the 2 receptors (Falanga et
al. 1992; Gold et al. 1997), were used as a positive
internal control. The final antibody titre used for each
antibody was 1 lg}ml, which corresponds to work
previously carried out using these same antibodies
(Gold et al. 1997). Negative controls were performed
using a rabbit IgG fraction (Dako, Ely, UK) at the
same concentration. Some sections were predigested
with 0–1% bovine testicular hyaluronidase (Cal-
biochem, Nottingham, UK) to unmask possible
hidden epitopes. Sections were incubated with primary
antibodies overnight at room temperature before
visualisation using reagents and protocols supplied
with the Vectastain peroxidase kit (Vector Labora-
tories, Peterborough, UK). Sections were counter-
stained with Harris’s haematoxylin. Positive cells
appear dark brown, while negative cells remain
purple}blue. To determine the number of positive
cells in the tendon matrix (excluding blood vessels), 4
random fields of each section were counted for positive
and negative cells on a ‹40 objective and the mean
calculated. Significance values between cadavers,
macroscopically ‘normal ’ sites and core lesion tissues
were calculated using Student’s t test on the raw data
values.
results
Histology and histochemisty
The histological appearance and staining properties
for the tendons are summarised in Table 1 and
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Table 1. Comparison of tissue histology}histochemistry and total cell number of tissues
Tissue Age (y) Duration of symptoms (y) Histology Cell no. (average}field)
Lesion site
A 36 1
All tissues showed a disorganised matrix
that was hypercellular, hypervascular
and had an increased
glycosaminoglycan content
65–3‡16–6
B 36 not known 83–8‡18–1
C 32 7 67–5‡12–8
D 38 not known 48–3‡11–9
E 29 6 38–8‡5–7
F 49 1–5 61–8‡25–2
G 49 not known 50–3‡10–7
Mean 59–4‡16–6**
‘Normal site ’
A 36 1
All tissue samples showed a generally
organised matrix, normal cellularity
with occasional hypercellular regions,
normal vascularity with focal
hypervascularity in one sample, no
glycosaminoglycan infiltration
32–8‡9–6
B 36 not known 43–8‡7–1
C 32 7 21–8‡5–1
D 38 not known 15‡5–7
E 29 6 21–5‡10–1
F 49 1–5 11–7‡3–1
G 49 not known 27–3‡4–8
Mean 26–1‡11–9
Cadaver
1 77 – All tissue samples had an organised
matrix, normal cellularity and
vascularity, no glycosaminoglycan
infiltration
17‡2–8
2 93 – 35‡10–6
3 56 – 30–8‡8–3
4 76 – 34‡13–1
Mean 30–9‡11–2
** Significant difference compared with macroscopically normal and cadaver tissue.
illustrated in Figure 1. The cadaver tendons showed
the characteristic histology of normal tendon with
dense, parallel packed fibres and sparse cellularity.
The cell nuclei were spindle shaped and cells were
located between collagen fibres in rows (Fig. 1a).
Blood vessels were infrequently seen and were re-
stricted to the endotenon at the edges of fibre bundles.
There was no infiltration with GAGs, seen by Alcian
blue staining, as has been shown previously (Movin et
al. 1997) (Fig. 1d ). Masson’s trichrome staining
showed mainly organised collagen fibril structures,
with some disorganised collagen staining at the cut
ends of the tissue (Fig. 1g). Tissue from the
macroscopically normal site generally showed tissue
architecture similar to that of the cadaver tissue.
There was a paucity of blood vessels (Fig 1b). Alcian
blue staining was again negative (Fig. 1e) and
Masson’s trichrome staining showed mainly organised
collagen (red) though small areas of disorganised
collagen (blue}green) (Fig. 1h). The specimens from
the lesion showed little of the organised matrix
structure seen in normal tendon. There was a
significant increase in cellularity (P% 0–05) compared
with both the macroscopically normal tissue and the
cadaver tissue (Table 1) and an increase in blood
vessels as has been previously reported in chronic
tendinosis (Astro$ m & Rausing, 1995; Khan et al.
1999). There was no indication of inflammatory cells
although cells were more rounded as opposed to the
normal spindle-like morphology (Fig. 1c). Alcian blue
staining showed areas of GAG infiltration in the
majority of specimens as previously described in
Achilles tendinopathy (Movin et al. 1997) (Fig. 1 f ).
Masson’s trichrome stain showed no indication of
organised collagen fibrils (Fig. 1 i ).
Immunolocalisation
Antibodies to TGF-b2 and TGF-bRII stained a
proportion of cells throughout the matrix (see Figs. 2,
3). Cell counts showed that in the cadaver sections,
25–8% of the cells on average were positive for TGF-
b2. In the distant site tissue the average was 46–7%
and in the core lesion site, 51–1%, both of which were
a significant increase in cell proportions over the
cadaver tissue sections (P% 0–001) (Table 2). No
significant difference existed between the macro-
scopically normal site and the core lesion site in the
pathological tendons. TGF-bRII stained positively in
26–4% of the cadaver tissue cells, 45–1% of the
macroscopically normal tissue cells and 39–2% of
lesion tissue cells. There was no significant difference
Transforming growth factor beta in tendon 235
Fig. 3. Immunolocalisation of TGF-b receptors showing a lack of tenocyte staining for TGF-bRI (a, c, e). TGF-bRII was localised in cells
throughout the tissue sections seen as dark brown staining of cells (b, d, f ). Blood vessels stained positively for both TGF-bRI (g) and TGF-
bRII (h), a and b are from a 56-y-old male cadaver, c and d are from the macroscopically normal site of a 38-y-old male, e and f are from
the core lesion site of the same 38-y-old male. Haematoxylin counterstain ‹400.
between these values when the raw data were
compared (P& 0–05).
Since there were differences in cellularity, nearly 3
times as many cells stained positively for TGF-b2 in
the core lesion tissue compared both with the
macroscopically normal site and the cadaver tissue
(P% 0–05). The number of cells expressing TGF-bRII
was similar to that expressing TGF-b2 in each of the
specimen groups, with a greater number of cells
expressing the receptor in the lesion site tissue
compared with the other sites (P% 0–05) (Table 2).
There was an absence of staining for TGF-b1, TGF-
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Table 2. Mean cell counts and percentage of cells expressing TGF-b2 and TGF-bII
TGF-b2 Positive
cells}field
% TGF-b2 positive
cells}field
TGF-bRII positive
cells}field
% TGF-bRII positive
cells}field
Lesion site 29–7‡14–4** 46–7‡26–5* 31–6‡23–8** 39–2‡28–1
‘Normal Site ’ 12–1‡8–2 51–1‡23–5* 11–1‡9–2 45–1‡29–2
Cadaver 12–1‡7–1 25–1‡9–3 12‡11–1 28–1‡11–6
*, significant difference compared with cadaver tissue; **, significant difference compared with macroscopically normal and cadaver tissue.
Fig. 4. Negative controls using a rabbit IgG fraction and
counterstained with haematoxylin. a is from a 77-y-old cadaver
section, b is from the core lesion of a 49-y-old male, c shows a blood
vessel from the same patient. There was no peroxidase (brown)
staining in any of the negative controls. ‹400.
b3 (Fig. 2) and TGF-bRI (Fig. 3) in cells throughout
the tissue matrix, although all 5 antibodies stained
positive in blood vessels (Figs. 2, 3). Negative controls
showed no background or nonspecific staining (Fig.
4).
discuss ion
We have shown here that of the 3 TGF-b isoforms,
only TGF-b2 was expressed by tenocytes in the
fibrillar matrix. TGF-b1 and TGF-b3 were restricted
to blood vessels, co-expressed with TGF-b2, as
described in previous studies (Falanga et al. 1992;
Gold et al. 1997). We have also shown that of the 2
TGF-b receptors, only TGF-bRII was present in
tenocytes although both were present in blood vessels.
Although we did not apply quantitative techniques
to this analysis, the percentage of cells expressing
TGF-b2 was significantly greater in patient tendons
compared with normal cadaver tendons. We also
found no difference in the percentage of positive cells
between macroscopically normal sites in patient
tendons, and specimens from the site of the lesion,
although the latter were more cellular. Significant
differences were not seen in the percentage of positive
cell stained for TGF-bRII. Since the cadaver tendons
were significantly older than the patient tendons, this
difference in TGF-b2 may reflect an ageing process
rather than an effect of the pathology. As Achilles
tendon injuries are common, it is also possible that
despite the absence of any known history of tendino-
pathy in the cadaver specimens, there may have been
previous pathological changes associated with some
of these samples, although at the histochemical level
there was no indication of obvious pathology.
TGF-b1 has been shown to be upregulated in
response to tissue damage in a number of connective
tissue pathologies including keloid scarring (Lee et al.
1999), hypertrophic scarring (Zhou et al. 1997) and
Dupuytren’s contracture (Badalamente et al. 1996).
Our study has shown that TGF-b1 is absent in chronic
Achilles tendinopathy, or at least is not present at
levels detectable by immunoperoxidase staining.
TGF-b2 however was clearly detectable and promi-
nently localized to cells throughout the tissues. TGF-
b2, along with TGF-b1, is an essential factor in the
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wound healing process and is associated with tissue
healing and scarring (Shah et al. 1995), and is often
prevalent in the earlier stages of wound healing along
with TGF-b3 (Levine et al. 1993). TGF-b2 has also
been linked to the induction of chondrogenesis and
osteogenesis (Joyce et al. 1990) and may have a role in
the chondrogenic change found in degenerate human
tendons (Chard et al. 1994; Riley et al. 1996).
However, we have found no evidence of markers of a
chondrocytic phenotype, such as type II collagen, at
the sites of chronic Achilles tendinosis (D. Ireland
et al. unpublished). TGF-b1 mRNA and protein have
been shown to be upregulated following acute tendon
laceration and repair. Both mRNA and protein were
localised to intrinsic tenocytes and invading fibro-
blasts from the tendon sheath (Chang et al. 1997).
However, this type of injury bears little resemblance
to the chronic disorders that we have dealt with here,
and therefore it is important to delineate the presence
or absence of TGF-b (and indeed other factors) in
these pathologies.
The factors that regulate TGF-b expression}activity
are not well understood. One study has shown that
both IL-1 and TNF-a are able to increase the synthesis
of TGF-b in endothelial cells (Phan et al. 1992).
Another study by Lemaire et al. (1996) showed
that both granulocyte macrophage-colony stimulating
factor and macrophage-colony stimulating factor
upregulated TGF-b1 mRNA in rat alveolar macro-
phages. A study on human articular chondrocytes has
shown that both IL-1 and IL-6 can selectively induce
TGF-b isoforms (Villiger et al. 1993). A number of
other factors have also been shown to regulate TGF-
b synthesis or secretion, including glucocorticoids
(Karim et al. 1997; Beer et al. 2000), hypoxia (Falanga
et al. 1991; Santilli et al. 1991; Klempt et al. 1992),
ethanol (Szabo et al. 1996) and hyperthermia
(Flanders et al. 1993). There is also evidence for
differential regulation of the TGF-b isoforms
(Falanga et al. 1991; Flanders et al. 1993; Villiger et
al. 1993), suggesting that mechanisms of stress, tissue
insult or cytokine exposure could induce a different
spectrum of TGF-b isoform expression.
The 3 isoforms of TGF-b have been shown to have
important, although differential, roles in wound
healing (Shah et al. 1995; O’Kane & Ferguson, 1997)
but their exact functions have still not been fully
elucidated. The lack of resolution in chronic tendinosis
suggests that there may be either a lack of TGF-b
activity, or a failure to respond to TGF-b. TGF-b2 is
certainly present, although whether in its active form
requires further investigation. Of possibly greater
significance is the evident lack of the type I TGF-b
receptor, at least at the level of antibody detection,
suggesting an absence or low level of expression of the
receptor. TGF-b requires both type I and type II
receptors to propagate its signal (Laiho et al. 1990;
Wrana et al. 1994), therefore the possible lack of (or
low levels of) the type I receptor suggests that signal
might not be induced even in the presence of active
TGF-b. The presence of receptors throughout wound
repair has been shown to occur at a later stage than
the presence of TGF-b ligand. Consequently it was
suggested that TGF-b ligand may upregulate the
TGF-b receptors for function or may reflect a lag
time due to latent TGF-b processing (Gold et al.
1997). However, we are dealing here with a chronic
condition, with symptoms of 12 mo up to 7 y.
Granulation tissue in wounded skin has been shown
to contain high levels of receptor (Schmid et al. 1998),
although in undamaged skin, only small numbers of
fibroblasts have detectable levels of receptors. Under
normal conditions then, fibroblasts may not express
one or both of the receptors, and we have shown that
normal tendon also has an absence (or at least an
undetectable level) of the type I receptor. The factors
regulating TGF-b receptor expression in tendon are
unknown, although a number of studies have been
performed in other models to examine the factors that
regulate receptor expression (Wu et al. 1997; Chang et
al. 1998; Yoshizawa et al 1998). Possibly of most
relevance is the finding that mechanical strain
increases the expression of TGF-b receptors in rat
mesangial cells (Riser et al. 1999). The loss of strain
across the pathological lesion in tendinosis could be a
factor influencing the lack of TGF-bRI expression at
these sites.
The cause of chronic tendon lesions is thought to be
repeated microtrauma (Kannus, 1997). It has been
speculated that microtrauma overwhelms the ability
of tendon to repair (Jarvinen et al. 1997). A similar
process has been shown to occur in chondrocytes
during osteoarthritis, where a stage of the disease is
reached where the chondrocytes fail to repair the
matrix damage (Mankin et al. 1971). Tissue repair is
a complex and tightly regulated process that requires
sequential overlapping phases (Robinson, 1993;
Mutsaers & Laurent, 1995). We postulate that the
healing phases in tendinosis have not occurred in the
correct manner. Inflammation is the first important
step in tissue healing; without this initial stage, the
tissue repair process may not proceed normally. In
all lesions we have examined, there has been no
evidence of inflammatory cells. In these chronic
tendon problems, it may be that the repair process
is not being triggered correctly or not being allowed
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to proceed correctly due to the lack of inflammatory
mediators, and it is this that accounts for the lack of
resolution.
In summary we have shown that there is a
differential expression of the 3 TGF-b isoforms and
their receptors in both normal and pathological
tendon. The number of cells expressing TGF-b2 in
chronic tendon pathology is increased which suggests
that TGF-b2 may have a role to play in mediating cell
activity during this disease process. However, the
lack of the type I receptor implies that TGF-b
signalling does not occur. This study has implications
for the treatment of tendinopathy with TGF-b, as
without the presence of both receptors, exogenous
TGF-b is unlikely to have an effect. We suggest that
greater investigation into the factors that regulate
TGF-b receptor expression is required to determine if
this is a potential target for chronic tendinosis therapy.
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